The Latest Biotechnology / Pharmaceuticals Articles from Streetwise Reports


Target Price Raised on Biotech Based on Management Update

Research Report
  ()
During its recent R&D Day, Prometheus Biosciences announced new strong trial data, another new indication for its lead therapeutic candidate and progress in developing a subcutaneous formulation of it, according to an Oppenheimer report.

Arena Pharma Takes Center Stage With Pfizer's $6.7B Cash Buyout

  ()
Arena Pharmaceuticals shares traded 80% higher after the company reported it agreed to be acquired by Pfizer Inc. for $100.00 per share in cash in a deal valued at $6.7 billion.

Biopharma Explains How Its Technology Evolved, Describes Current Programs

Research Report
  ()
F-star Therapeutics "has methodically delivered scientific/preclinical/early clinical data validating its platform bispecific technology," noted an Oppenheimer report.

Biopharma's Anti-PD-L1 Antibody Advances in Two Oncologic Indications

Research Report
  ()
Checkpoint Therapeutics' "cosibelimab represents a competitive asset on both efficacy and safety with an expected added advantage of lower net price," an H.C. Wainwright & Co. report noted.

Biopharma Partners to Commercialize Enzyme Used for Kidney Transplant Patients

Research Report
  ()
The partnership allows Hansa Biopharma to "enter new markets without the cost and risk of building out country-specific commercial organizations for a single product," an H.C. Wainwright & Co. report indicated.

California-Based Biopharma Advances Lead Asset in COVID-19, Other Indications

Research Report
  ()
Humanigen has applications for lenzilumab in the works with U.S., United Kingdom and European drug regulatory agencies, noted a ROTH Capital Partners report.

CRO's Shares Rise 18% on Preliminary Q4/FY Financial Results

  ()
Shares of contract research organization Inotiv Inc. traded higher after the company reported select preliminary unaudited financial results for Q4/21 and FY/21 which included a 90.7% YoY increase in revenue and a 123.0% increase in gross profit.

Biopharma Seeks to Add Idiopathic Hypersomnia to Narcolepsy Drug's Label

Research Report
  ()
Harmony Biosciences Holdings intends to conduct a Phase Three trial next year to evaluate Wakix as a treatment for idiopathic hypersomnia, according to an Oppenheimer report.

Biopharma Launches Clinical Trial of Primary Asset in Endometrial Cancer

Research Report
  ()
"Solid tumors offers a substantial opportunity for Karyopharm Therapeutics' Xpovio (selinexor) that perhaps investors have not yet realized," noted an H.C. Wainwright & Co. report.

Phase Two Studies Start for Therapy for Chemo-Treated Breast Cancer Patients

Research Report
  ()
New clinical trials for G1 Therapeutics’ Cosela are “central to our investment thesis,” H.C. Wainright & Co. noted in a new research report.

Biotech Firm’s T-Cell Therapy Gets Positive Results in B-Cell Non-Hodgkin’s Lymphoma Study

  ()
Adicet Bio Inc. shares traded 37% higher after the company reported positive interim data from its Phase 1 GLEAN Study of ADI-001, which the firm noted is the first-ever allogeneic, off-the-shelf, gamma delta CAR T investigational cell therapy.

Biopharma Launches COVID Vaccine Program in South Africa & Mexico

Research Report
  ()
Oramed Pharmaceuticals' oral vaccine offers "convenience and safety advantages as well as coverage of emergent variant strains," noted a Nov. 29, 2021 H.C. Wainwright & Co. report.

Antibody-Drug Conjugate Developer Achieves High Objective Response Rates in Ovarian Cancer Study

  ()
ImmunoGen Inc. shares traded 30% higher after the company announced positive topline data from its pivotal Phase 3 SORAYA Trial of mirvetuximab soravtansine in platinum-resistant ovarian cancer.

Emerging SARS-COv-2 Variant Is Revenue Growth Opportunity for Vaccine Developer

Research Report
  ()
Just a few days after the WHO deemed the COVID-19 Omicron variant a serious global health concern, leading mRNA-based vaccine developers BioNTech and Pfizer, along with rival Moderna, advised that if needed, the companies would be capable of developing a vaccine for the new mutating strains within roughly 100 days. H.C. Wainwright & Co. commented in a research note that it reiterates its "Buy" rating for BioNTech SE.

NRx Pharma's COVID-19 Vaccine Displays Effectiveness Against Delta Variant in Phase 2 Clinical Trial

  ()
Shares of NRx Pharmaceuticals Inc. traded 50% higher after the company commented on new data released by the Israel Institute for Biological Research regarding the effectiveness of its BriLife® COVID-19 Vaccine against the SARS-CoV-2 "Delta" variant.

Gene Therapy Firm's Shares Rise 120% on Topline Data From Pivotal Dystrophic EB Study

  ()
Shares of Krystal Biotech Inc. reached a new 52-week high after the company reported it met both primary and secondary endpoints in its pivotal GEM-3 trial of VYJUVEK™ in patients diagnosed with Dystrophic Epidermolysis Bullosa, a rare and severe skin disease.

Cellular Therapy Co. Earns Rare Pediatric Disease Designation for Infant Congenital Heart Treatment

  ()
Shares of Longeveron Inc. traded 50% higher after the company reported that the U.S. FDA approved its Lomecel-B for Rare Pediatric Disease Designation to treat a rare and life-threatening defect in infants called Hypoplastic Left Heart Syndrome.

RNA Silencing Platform Firm Receives US$3.3 Billion Buyout Offer From Novo Nordisk

  ()
Shares of Dicerna Pharmaceuticals Inc. traded 78% higher after the company reported it entered into a definitive agreement to be acquired by Novo Nordisk A/S of Denmark for $38.25 per share in cash.

Novavax Submits Request to EMA for Conditional Marketing Authorization for COVID-19 Vaccine

  ()
Shares of Novavax Inc. traded 10% higher after the firm confirmed that the European Medicines Agency is now reviewing its COVID-19 vaccine filing for conditional marketing authorization. The firm advised that an opinion from the agency is expected within a few weeks.

Biotech Co.'s Shares Gain 32% After Posting Meaningful Renal Response Rates in Ph. 2 Lupus Study

  ()
Shares of Kezar Life Sciences Inc. rose to a new 52-week high after the company reported promising interim results from its Phase 2 trial of KZR-616 in patients with lupus nephritis.

EyePoint Pharma Reduces Wet AMD Treatment Burden by 79% after 6 Mo.'s in Phase 1 Trial

  ()
Shares of EyePoint Pharmaceuticals Inc. reached a new 52-week intraday high after the company reported positive data from its Phase 1 DAVIO study of EYP-1901 in Wet AMD and announced plans to move forward to additional Phase 2 clinical trials in 2022.

Trial of Psilocybin Therapeutic in Treatment Resistant Depression Yields Positive Topline Results

Research Report
  ()
"We believe this data begins to form the basis of an approvable program for Compass Pathways' COMP360" in this indication, noted a BTIG report.

Advanced Medical Genetics Co. Notches 66% YoY Increase in Q3 Revenue

Research Report
  ()
Invitae Corp. reported Q3/21 financial results that highlighted an 89% YoY increase in billable volume to 296,000 tests. Ladenburg Thalmann & Co. Inc. stated in a research note that it has a "Buy" rating for the company with a $55.00/share price target.

Contakt World Technologies Partnership Will Help Satisfy Demand for Vaccine Passport Technology

  ()
Contakt World plans to build a diversified health technology SaaS platform and address inequity of health access through technology.

Microbiome Therapeutics Co.'s Shares Rise on Q3 Earnings & Partnership With Swiss Manufacturing Firm

  ()
Shares of Seres Therapeutics Inc. traded 20% higher after the company reported Q3/21 financial results and announced it is partnering with Bacthera in Switzerland to manufacture medicine for use in c.Diff treatment.

Showing Results: 26 to 50 of 112 Prev Next

Get Our Streetwise Reports Life Sciences Report Newsletter Free and be the first to know!

A valid email address is required to subscribe

More Experts